CMP: ₹ 17099 Target: ₹ 18000 (5%)

Target Period: 12 months

July 29, 2020

## Supply chain constraints in April hit the sales

Nestlé India (NIL) reported muted revenue growth of 2% in Q2CY20 with manufacturing & supply chain operations remaining disrupted in April. The domestic sales growth was 2.6% while exports de-grew 9.3%. We believe supply in April was normal only for milk products & all other categories witnessed resumption of manufacturing in slow & gradual manner. The quarter witnessed a strong growth in 'Everyday', 'Nestlé a+' & 'Milkmaid' mainly due to very high sales in initial weeks of April. We believe the company anticipated large scale disruption in milk supply or shift in consumer demand from pouch to powder & UHT Milk. However, pouch milk supply disruption did not last longer than few weeks, resulting in piling up of 'Everyday' inventory at the end of distributors. We believe milk products would see inventory rationalisation at the distributor level given demand conditions from hotels, restaurants & airline remain muted. Operating profit saw growth of 7.2% with margins expanding 127 bps. The margin expansion was led by cost cutting measures & reduction in A&P spend (overhead spends down 487 bps) partially offset by the 193 bps contraction in gross margins. Given the reduction in corporate tax rate, net profit increased 11.1% to ₹ 486.6 crore (I-direct estimate : ₹ 502.7 crore). Notably, e-com channel sales grew by 122% contributing now 3.6% of sales.

### Strong demand conditions in prepared foods

Though the supply & demand conditions for most categories are normalising, prepared dishes segment is having a different tale. One of the clear trends in the last four months has been increasing demand for convenient food. Maggi Noodles, ketchup, Masala magic witnessed strong demand conditions in the June quarter. However, the company could not supply the products in April given most manufacturing facilities either remain closed or are working on very low utilisation. Though manufacturing operations returned to normal in June-July, demand is still outpacing supply. We believe near term supply constrains in the noodles segment could potentially result in market share loss. However, on a long term perspective, we believe the company's product portfolio with strong growth opportunity in noodles, chocolate & UHT milk is likely to witness healthy growth. We expect 10.8% CAGR sales growth in CY19-21E.

#### Benign milk prices, cut in A&P spend to perk up margins

In Q2CY20, gross margins contracted 193 bps despite milk prices declining substantially. We believe the company would have been holding high SMP inventory in March in anticipation of elevated milk prices. We believe the company would see uptick in operating margins given lower milk prices, reduction in A&P spend (trade promotions have been lower than normal) & other cost cutting measures. We expect operating margins to expand 150 bps to 24.7% during CY20-22E.

#### Valuation & Outlook

From the average factory utilisation level of 75% in Q2CY20, manufacturing has returned to near normal currently. We remain positive on growth prospects driven by continued in-home consumption. The stock is trading at premium valuation multiples. We maintain our target price of ₹ 18000/share with a **HOLD** recommendation.

34.9

**Key Financial Summary Key Financials CY17 CY18 CY19** CY20E CY21E CAGR (CY19-21E) **Net Sales** 9952.5 11216.2 12295.3 13286.5 15103.2 10.8% 14.4% **FBITDA** 2248.3 2759.8 2864.3 3263.5 3748.7 EBITDA Margin % 22.6 24.6 24.6 24.8 23.3 Net Profit 1225.2 1606.9 1969.6 2220.4 2592.3 14.7% EPS (₹) 166.66 204.27 230.29 268.85 127.07 P/E 102.6 83.7 63.6 134.6 74.3 RoNW % 123.6 37.5 45.6 101.9 114.2

56.9

59.3

65.9

42.9

HOLD



Particulars	
Particulars (₹ crore)	Amount
Market Capitalization	164869
Total Debt (CY19)	53.1
Cash & Investments (CY19)	2,315.5
EV	162,606.2
52 week H/L (₹)	18369 / 10120
Equity capital	96.4
Face value (₹)	10.0

#### **Key Highlights**

- Domestic sales increased by 2.6% impacted by manufacturing & supply chain disruptions in April
- Export sales declined by 9.3%%
- Operating margins expanded by 127 bps with substantial reduction in A&P spends
- Maintain HOLD recommendation with target price of ₹ 18000/share

#### **Research Analyst**

Sanjay Manyal sanjay.manyal@icicisecurities.com

Source: Company, ICICI Direct Research

RoCE (%)



Exhibit 1: Variance A	nalysis						
Particulars (₹ crore)	Q2CY20	Q2CY20E	Q1CY19	YoY (%)	Q1CY20	QoQ (%)	Comments
Total Operating Income	3,050.5	3,188.8	3,000.9	1.7	3,325.3	-8.3	Net sales witnessed a growth of 2% impacted by manufacturing disruption in April
Operating Income	9.0	0.0	18.0	-49.9	19.5	-53.7	
							Gross margins contracted by 193 bps due to high milk
Raw Material Expenses	1,331.9	1,320.2	1,252.2	6.4	1,453.3	-8.4	prices. We believe the company would have been holding high inventory levels
Employee Expenses	369.6	325.5	314.6	17.5	358.4	3.1	
Other operating Expenses	601.4	755.7	736.8	-18.4	720.3	-16.5	Overhead spends were down by 18.4% with substaintial reduction in A&P spends & cost cutting measures
EBITDA	747.6	787.3	697.3	7.2	793.3	-5.8	
EBITDA Margin (%)	24.5	24.7	23.2	127 bps	23.9	65 bps	Operating profit expanded by 127 bps led by lower A&P spends
Depreciation	92.4	83.6	80.8	14.4	91.4	1.2	
Interest	40.8	31.6	29.9	36.4	41.0	-0.4	
Other Income	37.9	0.0	72.6	-47.7	42.9	-11.5	
Exceptional Items	0.0	0.0	0.0	NA	0.0	NA	
PBT	652.3	672.1	659.2	-1.0	703.9	-7.3	
Tax Outgo	165.7	169.4	221.3	-25.1	178.4	-7.1	
PAT	486.6	502.7	437.8	11.1	525.4	-7.4	Net profit grew by 11.1% on account of reduction in tax rates in 2019
Adjusted PAT	486.6	502.7	437.8	11.1	525.4	-7.4	


Source: Company, ICICI Direct Research

Exhibit 2: Chang	ge in estir	mates					
		CY20E			CY21E		
(₹ Crore)	Old	New	% Change	Old	New	% Change	Comments
Net Sales	13,300.0	13,286.5	-0.1	15,115.9	15,103.2	-0.1	No major change in estimates
EBITDA	3271.3	3263.5	-0.2	3755.9	3748.7	-0.2	
EBITDA Margin(%)	24.6	24.6	-3 bps	24.8	24.8	-3 bps	
PAT	2226.3	2220.4	-0.3	2597.7	2592.3	-0.2	
EPS (₹)	230.9	230.3	-0.3	269.4	268.9	-0.2	

Source: Company, ICICI Direct Research

Exhibit 3: Assumptions	5								
			Current				Earlier		
	CY16	CY17	CY18	CY19E	CY20E	CY21E	CY20E	CY21E	Comments
Gross Sales (₹ crore)									
Milk Product and Nutrition	4,635.0	4,819.6	5,187.6	5,651.8	6,228.9	6,996.3	6,183.2	6,945.0	
Beverages	1,286.1	1,387.0	1,522.6	1,501.8	1,516.8	1,687.3	1,679.3	1,868.1	No major change in estimates
Prepared dishes	2,317.6	2,707.1	3,105.3	3,498.2	3,848.0	4,518.3	3,832.5	4,500.1	
Chocolate & confectionery	1,170.9	1,221.4	1,400.7	1,643.5	1,692.8	1,901.3	1,604.9	1,802.7	
Volume Growth (%)									
Overall Volume Growth	25.0	10.9	11.1	7.0	7.9	11.4	7.9	11.4	
Milk Product and Nutrition	-2.4	1.6	4.8	1.4	7.0	8.0	7.0	8.0	
Beverages	-0.2	10.6	10.6	-2.3	0.0	8.0	0.0	8.0	
Prepared dishes	71.5	19.0	14.5	9.6	10.0	14.0	10.0	14.0	
Chocolate & confectionery	6.7	4.3	14.7	16.2	3.0	8.0	3.0	8.0	

### **Key Metrics**




Source: Company, ICICI Direct Research



Source: Company, ICICI Direct Research

#### Milk products & nutrition




Source: Company, ICICI Direct Research

#### Exhibit 7: Revenue growth to be mix of volume & price growth 14 12 10 8 6 4 8.0 7.0 2 0 -2.4 -2 CY16 CY17 CY18 CY20E CY21E CY19


■Volume growth (%) ■ Realisation growth(%)

Source: Company, ICICI Direct Research

#### **Beverages**




Source: Company, ICICI Direct Research



#### **Prepared dishes**

#### Exhibit 10: Volumes to grow with high in-home consumption



Source: Company, ICICI Direct Research

# Exhibit 11: Growth aided by strong demand for convenient food




Source: Company, ICICI Direct Research

#### **Chocolate & confectionery**




Source: Company, ICICI Direct Research

#### Exhibit 13: Volume growth to return in CY21E




Source: Company, ICICI Direct Research

#### Exhibit 14: : EBITDA margin to remain at elevated levels



Source: Company, ICICI Direct Research


#### Exhibit 15: PAT to grow at 14.7% CAGR over CY19-21E



Source: Company, ICICI Direct Research

Exhibit 16:	: Valuation							
	Sales	Growth	Growth EPS Grov		PE	EV/EBITDA	RoNW	RoCE
	(₹ cr)	(%)	(₹)	(%)	(x)	(x)	(%)	(%)
CY18	11216.2	12.7	166.7	31.2	102.6	59.2	45.6	42.9
CY19	12295.3	9.6	204.3	22.6	83.7	57.1	101.9	56.9
CY20E	13286.5	8.1	230.3	12.7	74.3	50.2	114.2	59.3
CY21E	15103.2	13.7	268.9	16.7	63.6	43.7	123.6	65.9





Source: Bloomberg, Company, ICICI Direct Research

Rank	Investor Name	Filing Date	% O/S	Position (m)	Change (m)
1	Nestle Sa	31-Mar-20	34.3	33.1	0.0
2	Maggi Enterprises Lt	31-Mar-20	28.5	27.5	0.0
3	Sbi Funds Management	30-Jun-20	8.9	8.6	7.1
4	Life Insurance Corp	31-Dec-19	3.0	2.9	0.1
5	50 Sbi-Etf Nifty	31-Dec-19	1.5	1.5	1.5
6	Axis Asset Managemen	31-May-20	1.3	1.3	0.1
7	Arisaig India Fund L	30-Jun-19	1.0	1.0	-0.1
8	Vanguard Group	30-Jun-20	0.9	0.8	0.0
9	Blackrock	13-Jul-20	0.8	0.8	0.0
10	Uti Asset Management	31-May-20	0.5	0.4	0.0

Source: Reuters, ICICI Direct Research

Exhibit 19: Sharehol	ding Pattern				
(in %)	Jun-19	Sep-19	Dec-19	Mar-20	Jun-20
Promoter	62.8	62.8	62.8	62.76	62.76
FII	13.0	12.6	12.1	11.81	12.1
DII	7.5	8.5	8.9	9.12	8.7
Others	16.8	16.1	16.3	16.3	16.4

## Financial summary

Exhibit 20: Profit and los	ss stateme	nt		₹ crore
(Year-end December)	CY18	CY19	CY20E	CY21E
Total operating Income	11,292.3	12,368.9	13,367.5	15,192.3
Growth (%)	12.8	9.5	8.1	13.7
Raw Material Expenses	3,823.2	5,223.9	5,719.4	6,444.5
Employee Expenses	1,124.2	1,263.0	1,302.1	1,434.8
Marketing Expenses	1,285.2	0.0	0.0	0.0
Administrative Expenses	1,086.0	63.2	93.0	90.6
Other expenses	1,214.0	2,954.5	2,989.5	3,473.7
Total Operating Expenditure	8,532.5	9,504.6	10,104.0	11,443.6
EBITDA	2,759.8	2,864.3	3,263.5	3,748.7
Growth (%)	22.8	3.8	13.9	14.9
Depreciation	346.8	316.4	334.5	338.8
Interest	112.0	119.8	126.5	142.8
Other Income	258.9	246.9	166.0	198.6
PBT	2,532.6	2,675.0	2,968.5	3,465.6
Others	103.7	0.0	0.0	0.0
Total Tax	822.0	705.4	748.1	873.3
PAT	1,606.9	1,969.6	2,220.4	2,592.3
Growth (%)	31.2	22.6	12.7	16.7
EPS (₹)	166.7	204.3	230.3	268.9

Source: Company, ICICI Direct Research

Exhibit 21: Cash flow state	ement			₹ crore
(Year-end December)	CY18	CY19	CY20E	CY21E
Profit after Tax	1,606.9	1,969.6	2,220.4	2,592.3
Add: Depreciation	346.8	316.4	334.5	338.8
(Inc)/dec in Current Assets	-646.9	617.8	-548.6	-587.8
Inc/(dec) in CL	362.2	292.6	109.4	267.2
CF from operating activities	1,669.0	3,196.2	2,115.7	2,610.6
(Inc)/dec in LT loans & adv	6.2	-6.8	47.0	0.0
(Inc)/dec in other investments	-148.1	-10.2	-20.0	-20.0
(Inc)/dec in Fixed Assets	-142.2	-180.6	-477.6	-320.0
Others	110.1	401.0	299.6	100.0
CF from investing activities	-162.6	194.8	-70.6	-240.0
Issue/(Buy back) of Equity	0.0	0.0	0.0	0.0
Inc/(dec) in loan funds	0.0	18.0	0.0	0.0
Dividend paid & dividend tax	-1,313.4	-3,957.1	-2,207.5	-2,439.3
Inc/(dec) in Sec. premium	0.0	0.0	0.0	0.0
Others	-40.4	246.0	0.0	0.0
CF from financing activities	-1,353.7	-3,693.0	-2,207.5	-2,439.3
Net Cash flow	152.7	-302.0	-162.4	-68.8
Opening Cash	1,457.4	1,610.1	1,308.1	1,145.7
Closing Cash	1,610.1	1,308.1	1,145.7	1,076.9

Source: Company, ICICI Direct Research

Exhibit 22: Balance she	et			₹ crore
(Year-end December)	CY18	CY19	CY20E	CY21E
Liabilities				
Equity Capital	96.4	96.4	96.4	96.4
Reserve and Surplus	3,577.3	1,835.8	1,848.7	2,001.
Total Shareholders funds	3,673.8	1,932.3	1,945.2	2,098.
Total Debt	35.1	53.1	53.1	53.
Deferred Tax Liability	58.8	18.0	18.0	18.0
Long Term Provisions	2,464.9	2,906.9	3,206.9	3,306.
Total Liabilities	6,233.1	4,910.7	5,223.2	5,476.
Assets				
Gross Block	3,485.4	3,785.4	4,085.4	4,385.4
Less: Acc Depreciation	1,084.8	1,401.2	1,735.7	2,074.
Net Block	2,400.6	2,226.7	2,349.7	2,310.
Capital WIP	105.2	143.3	163.3	183.
Total Fixed Assets	2,505.8	2,370.0	2,513.0	2,494.
LT Loans & Advances	40.1	47.0	0.0	0.
Inventory	965.6	1,283.1	1,383.2	1,655.
Debtors	124.6	124.3	127.4	144.
Loans and Advances	17.9	12.5	145.6	165.
Current Investments	2,018.9	1,089.3	1,401.4	1,680.
Cash	1,610.1	1,308.1	1,145.7	1,076.
Total Current Assets	4,737.0	3,817.2	4,203.4	4,722.
Creditors	1,240.4	1,494.7	1,456.1	1,655.
Provisions	157.3	85.5	254.8	248.
Other Current Liabilities	457.3	567.4	546.0	620.
Total Current Liabilities	1,855.0	2,147.5	2,256.9	2,524.
Net Current Assets	2,882.0	1,669.7	1,946.5	2,198.
Application of Funds	6,233.1	4,910.7	5,223.2	5,476.

Source: Company, ICICI Direct Research

Exhibit 23: Key ratios			;	₹ crore
(Year-end December)	CY18	CY19	CY20E	CY21E
Per share data (₹)				
EPS	166.7	204.3	230.3	268.9
Cash EPS	202.6	237.1	265.0	304.0
BV	381.0	200.4	201.7	217.6
DPS	113.0	342.0	190.0	210.0
Cash Per Share	112.5	145.3	180.0	215.2
Operating Ratios (%)				
EBITDA Margin	24.4	23.2	24.4	24.7
PBT / Net Sales	21.7	21.8	22.3	22.9
PAT Margin	14.3	16.0	16.7	17.2
Inventory days	31.4	38.1	38.0	40.0
Debtor days	4.1	3.7	3.5	3.5
Creditor days	40.4	44.4	40.0	40.0
Return Ratios (%)				
RoE	45.6	101.9	114.2	123.6
RoCE	42.9	56.9	59.3	65.9
RoIC	53.4	70.4	74.8	80.9
Valuation Ratios (x)				
P/E	102.6	83.7	74.3	63.6
EV / EBITDA	59.2	57.1	50.2	43.7
EV / Net Sales	14.6	13.3	12.3	10.8
Market Cap / Sales	14.7	13.4	12.4	10.9
Price to Book Value	44.9	85.3	84.8	78.6
Solvency Ratios				
Debt/EBITDA	0.0	0.0	0.0	0.0
Debt / Equity	0.0	0.0	0.0	0.0
Current Ratio	1.7	1.2	1.4	1.4
Quick Ratio	1.2	0.6	0.7	0.8

Sector / Company	CMP	TP		M Cap		EPS (₹)			<b>P/E</b> (x)		Pric	e/Sales	(x)	F	RoCE (%	)		<b>RoE</b> (%)	)
Sector / Company	(₹)	(₹)	Rating	(₹ Cr)	FY20	FY21E	FY22E	FY20	FY21E	FY22E	FY20	FY21E	FY21E	FY20	FY21E	FY22E	FY20	FY21E	FY22E
Colgate (COLPAL)	1,392	1,350	Hold	37,620	30.0	29.3	33.6	46.4	47.4	41.4	8.4	8.2	7.5	60.7	66.2	77.5	51.2	50.8	59.5
Dabur India (DABIND)	475	520	Buy	83,283	8.2	8.8	10.3	58.0	53.9	46.3	9.6	9.5	8.2	26.1	25.7	28.3	21.9	22.5	24.8
Hindustan Unilever (HINLEV)	2,243	2,410	Hold	519,159	31.2	32.4	40.1	71.9	69.2	55.9	13.6	12.2	10.6	89.5	26.7	33.0	85.7	20.3	25.4
ITC Limited (ITC)	195	250	Buy	245,475	12.5	11.7	13.0	15.7	16.6	15.0	5.3	5.2	4.6	29.4	28.3	36.1	23.8	21.7	27.7
Jyothy Lab (JYOLAB)	121	115	Hold	4,535	4.3	4.1	5.7	28.2	29.3	21.0	2.7	2.9	2.4	24.3	23.3	28.8	21.7	18.8	23.8
Marico (MARLIM)	362	380	Hold	45,286	8.1	8.5	9.6	44.8	42.6	37.8	6.2	6.1	5.5	41.0	42.3	46.2	34.5	35.6	39.5
Nestle (NESIND)	17,099	18,000	Hold	164,869	204.3	230.3	268.9	83.7	74.3	63.6	13.4	12.4	10.9	56.9	59.3	65.9	101.9	114.2	123.6
Tata Consumer Products (TATGLO	413	440	Buy	37,667	5.0	8.7	10.9	82.7	47.6	37.9	3.9	3.7	3.4	6.9	7.9	8.8	4.6	5.9	7.1
VST Industries (VSTIND)	3,202	4,000	Buy	4,942	196.9	124.8	216.3	16.3	25.7	14.8	4.0	4.5	3.5	52.1	32.9	45.6	38.6	24.3	33.7
Varun Beverage (VARBEV)	702	571	Reduce	20,122	16.4	9.7	17.8	42.9	72.1	39.4	2.8	3.3	2.7	15.5	11.3	16.3	14.2	8.8	14.2
Zydus Wellness (ZYDWEL)	1,624	1,530	Buy	9,445	24.6	31.6	50.3	66.1	51.3	32.3	5.3	5.7	4.6	5.9	5.7	7.4	5.4	5.1	7.5

#### **RATING RATIONALE**

ICICI Direct endeavours to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according to their notional target price vs. current market price and then categorizes them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15%

Hold: -5% to 15%;

Reduce: -15% to -5%;

Sell: <-15%



Pankaj Pandey

Head - Research

pankaj.pandey@icicisecurities.com

ICICI Direct Research Desk, ICICI Securities Limited, 1st Floor, Akruti Trade Centre, Road No 7, MIDC, Andheri (East) Mumbai – 400 093 research@icicidirect.com



#### ANALYST CERTIFICATION

I/We, Sanjay Manyal, MBA (Finance) MBA (Finance), Research Analyst, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

#### Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. ICICI Securities Limited is a SEBI registered Research Analyst with SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or comanaging public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report

Since associates of ICICI Securities are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.